Deere & Company DE is scheduled to report first-quarter fiscal 2020 results on Feb 21, before the opening bell.
Which Way are the Estimates Trending?
The Zacks Consensus Estimate for Deere’s earnings per share is pegged at $1.30 for the fiscal first quarter, suggesting a 15.6% year-over-year decline. The Zacks Consensus Estimate for total revenues is pegged at $6.20 billion for the period, down from the $6.94 billion reported in the year-ago quarter.
A Sneak Peak into Q4 Performance
In the last reported quarter, Deere’s earnings and revenues surpassed the Zacks Consensus Estimate. The company’s top line improved, while the bottom line declined year on year.
Share Price Performance
Deere’s shares have gained 5.7% over the past year compared with the industry’s 5.1% growth.
Let’s see how things have shaped up prior to this announcement.
Key Factors to Consider
Lower commodity prices, poor growing and harvesting as well as tariffs and trade-related concerns have made farmers cautious about spending on farm equipment, straining Deere’s revenues. Also, inflated raw-material costs, resulting from tariff implementations, are likely to have dragged down the company’s margins in the fiscal first quarter. Nevertheless, cost management, footprint assessment and continued investment in innovative technology and solutions are likely to have driven the company’s performance. Further, replacement demand will likely reflect on the to-be-reported quarter’s revenues.
The Zacks Consensus Estimate for the Agriculture and Turf equipment segment’s net sales is currently pegged at $4.21 billion for the quarter to be reported, suggesting a decline from the year-earlier quarter’s $4.68 billion. The Agriculture and Turf equipment segment’s operating income is projected at $280 million, down from the prior-year quarter’s $348 million.
The Zacks Consensus Estimate for the Construction & Forestry segment’s sales is pegged at $1.94 billion for the November-January period, suggesting a drop of 14% from the year-ago quarter’s reported figure. The Construction & Forestry segment is estimated to report an operating profit of $168 million, indicating a fall of 26.6% from the year-earlier quarter’s $229 million. The segment is anticipated to have declined in the fiscal first quarter owing to sluggish construction activity and underproduction to retail volume.
The Zacks Consensus Estimate for net sales of equipment operations (which comprise Agriculture and Turf, Construction and Forestry) is $6.15 billion, calling for a decline of 11.3% from the year-ago quarter’s reported figure. Softer large equipment demand might have hampered industry sales of agricultural equipment in the United States and Canada.
The Zacks Consensus Estimate for the Financial Services segment’s sales is pinned at $846 million, suggesting a 1.05% decline, year on year. The Zacks Consensus Estimate for the segment’s operating profit is currently pegged at $181 million, indicating a decrease of 5.7% from the prior-year quarter.
Deere & Company Price and EPS Surprise
Our proven model doesn’t conclusively predict an earnings beat for Deere this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: The Earnings ESP for Deere is 0.00%. This is because currently the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at $1.30.
Zacks Rank: Deere currently carries a Zacks Rank of 4 (Sell).
Stocks Worth a Look
Here are some stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Applied Optoelectronics, Inc. AAOI has an Earnings ESP of +8.12% and carries a Zacks Rank #3, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
Aduro BioTech, Inc. has an Earnings ESP of +23.08% and holds a Zacks Rank of 3, at present.
The AES Corporation AES has an Earnings ESP of +0.76% and is currently a Zacks #3 Ranked stock.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>